- Horizon Discovery said it had agreed to sell its In Vivo business to Envigo for a 'nominal' amount.

In Vivo provided genetically engineered rodent models from its premises in St Louis, Missouri and Boyertown, Pennsylvania.

In Vivo would be incorporated into Envigo with the business unit's assets and employees also expected to be transferred.

The sale would enable Horizon to 'continue crucial aspects of its animal model screening work in conjunction with Envigo, and to generate additional business opportunities of benefit to both companies,' Horizon said.

The transaction was expected to be completed within 30 to 45 days and was subject to customary closing conditions.

At 9:02am: [LON:HZD] Horizon Discovery Group Plc share price was +0.2p at 169.2p

Story provided by